Advertisement

Psychopharmacology

, Volume 172, Issue 4, pp 400–408 | Cite as

Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial

  • J. B. Deakin
  • S. Rahman
  • P. J. Nestor
  • J. R. Hodges
  • B. J. Sahakian
Original Investigation

Abstract

Rationale

Patients with frontal variant frontotemporal dementia (fvFTD) present with disinhibition, impulsiveness, apathy, altered appetite and stereotypic behaviors. A non-randomized clinical trial found improvement in these symptoms after treatment with a selective serotonin reuptake inhibitor (SSRI).

Objectives

We aimed to subject a SSRI, paroxetine, to a more rigorous test of its efficacy using a double-blind, placebo-controlled experimental design.

Methods

Ten subjects meeting the consensus criteria for FTD were entered into a double-blind, placebo-controlled crossover trial. Doses of paroxetine were progressively increased to 40 mg daily. The same regimen was used for placebo capsules. Subjects were assessed with a battery of cognitive tests in the sixth week of paroxetine and placebo treatment. At each assessment, caregivers were interviewed using the Neuropsychiatric Inventory and asked to complete the Cambridge Behavioral Inventory.

Results

There were no significant differences on the Neuropsychiatric Inventory or the Cambridge Behavioral Inventory. Paroxetine caused a decrease in accuracy on the paired associates learning task, reversal learning and a delayed pattern recognition task. There were no changes on the decision-making task, in spatial span, spatial recognition, spatial working memory, digit span and verbal fluency.

Conclusions

This study finds no evidence for the efficacy of paroxetine in the treatment of fvFTD. The results suggest that a chronic course of paroxetine may selectively impair paired associates learning, reversal learning and delayed pattern recognition. This pattern of deficits closely resembles that seen after tryptophan depletion. Results are discussed with respect to current theories on serotonergic modulation of orbitofrontal/ventromedial prefrontal cortex.

Keywords

Decision-making Frontotemporal dementia Paroxetine Serotonin 

Notes

Acknowledgements

Funding was provided by a Wellcome Trust programme grant (019407) to Prof. T.W. Robbins, Prof. B.J. Everitt, Dr. A.C. Roberts and Prof. B.J. Sahakian and carried out within a MRC Center for Behavioural and Clinical Neuroscience. J.B.D. was funded by Merck Sharp and Dohme, a James Baird Award from the University of Cambridge School of Clinical Medicine and an Oon Khye Beng studentship. S.R. was funded by the MRC and the James Baird Fund. John Hodges funding was provided by a MRC program grant. The authors would like to thank Dr. S. Bozeat for help with collecting the data, Dr. M. Aitken for statistical advice and Prof. Robbins for his comments on the results.

References

  1. Bechara A, Damasio H, Damasio AR, Lee GP (1999) Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. J Neurosci 19:5473–5481PubMedGoogle Scholar
  2. Benton AL (1968) Differential behavioural effects in frontal lobe disease. Neuropsychologia 6:53–60CrossRefGoogle Scholar
  3. Blier P, de Montigny C (1998) Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 44:313–323PubMedGoogle Scholar
  4. Blier P, de Montigny C (1999) Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21:91S–98SGoogle Scholar
  5. Bozeat S, Gregory CA, Ralph MA, Hodges JR (2000) Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer’s disease? J Neurol Neurosurg Psychiatry 69:178–186CrossRefPubMedGoogle Scholar
  6. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314PubMedGoogle Scholar
  7. Dolan M, Anderson IM, Deakin JF (2001) Relationship between 5-HT function and impulsivity and aggression in male offenders with personality disorders. Br J Psychiatry 178:352–359CrossRefPubMedGoogle Scholar
  8. Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW (1989) Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson’s disease: evidence for a specific attentional dysfunction. Neuropsychologia 27:1329–1343PubMedGoogle Scholar
  9. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131:196–206PubMedGoogle Scholar
  10. Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ (1995) Computerized delayed matching to sample and paired associate performance in the early detection of dementia. Appl Neuropsychol 2:72–78Google Scholar
  11. Gregory CA (1999) Frontal variant of frontotemporal dementia: a cross-sectional and longitudinal study of neuropsychiatric features. Psychol Med 29:1205–1217CrossRefPubMedGoogle Scholar
  12. Gregory CA, Serra-Mestres J, Hodges JR (1999) Early diagnosis of the frontal variant of frontotemporal dementia: how sensitive are standard neuroimaging and neuropsychologic tests? Neuropsychiatry Neuropsychol Behav Neurol 12:128–135PubMedGoogle Scholar
  13. Grundman M, Corey-Bloom J, Thal LJ (1998) Perspectives in clinical Alzheimer’s disease research and the development of antidementia drugs. J Neural Transm Suppl 53:255–275PubMedGoogle Scholar
  14. Hodges JR, Miller B (2001) The classification, genetics and neuropathology of frontotemporal dementia. Introduction to the special topic papers: part I. Neurocase 7:31–35PubMedGoogle Scholar
  15. Joyce EM, Robbins TW (1991) Frontal lobe function in Korsakoff and non-Korsakoff alcoholics: planning and spatial working memory. Neuropsychologia 29:709–723CrossRefPubMedGoogle Scholar
  16. Levy ML, Miller BL, Cummings JL, Fairbanks LA, Craig A (1996) Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch Neurol 53:687–690PubMedGoogle Scholar
  17. Manes F, Sahakian B, Clark L, Rogers R, Aitken M, Robbins T (2002) Decision-making processes following damage to the prefrontal cortex. Brain 125:624–639CrossRefPubMedGoogle Scholar
  18. Mann JJ (1999) Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 21:99S–105SPubMedGoogle Scholar
  19. Mavaddat N, Kirkpatrick PJ, Rogers RD, Sahakian BJ (2000) Deficits in decision-making in patients with aneurysms of the anterior communicating artery. Brain 123:2109–2117CrossRefPubMedGoogle Scholar
  20. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356:2031–2036PubMedGoogle Scholar
  21. Milner B (1964) Effects of different brain lesions on card sorting. Arch Neurol 9:100–110Google Scholar
  22. Montgomery SA (1996) Long-term management of obsessive-compulsive disorder. Int Clin Psychopharmacol 11[Suppl 5]:23–29Google Scholar
  23. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A (2003) Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 49:13–19CrossRefPubMedGoogle Scholar
  24. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMedGoogle Scholar
  25. Neary D, Snowden JS, Mann DM (2000) Classification and description of frontotemporal dementias. Ann New York Acad Sci 920:46–51Google Scholar
  26. Orrell MW, Sahakian BJ (1991) Dementia of frontal lobe type (editorial). Psychol Med 21:553–556PubMedGoogle Scholar
  27. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW (1990) Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 28:1021–1034PubMedGoogle Scholar
  28. Park SB, Coull JT, McShane RH, Young AH, Sahakian BJ, Robbins TW, Cowen PJ (1994) Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology 33:575–588PubMedGoogle Scholar
  29. Perry RJ, Hodges JR (1999) Attention and executive deficits in Alzheimer’s disease. A critical review. Brain 122:383–404CrossRefPubMedGoogle Scholar
  30. Plaisted KC, Sahakian BJ (1997) Dementia of the frontal lobe type-living in the here and now. Aging Mental Health 1:293–295CrossRefGoogle Scholar
  31. Rahman S, Sahakian BJ, Hodges JR, Rogers RD, Robbins TW (1999) Specific cognitive deficits in mild frontal variant frontotemporal dementia. Brain 122:1469–1493PubMedGoogle Scholar
  32. Ratnavalli E, Brayne C, Dawson K, Hodges JR (2002) The prevalence of frontotemporal dementia. Neurology 58:1615–1621PubMedGoogle Scholar
  33. Robbins TW (2000) Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res 133:130–138PubMedGoogle Scholar
  34. Rogers RD, Robbins TW (2001) Investigating the neurocognitive deficits associated with chronic drug misuse. Curr Opin Neurobiol 11:250–257PubMedGoogle Scholar
  35. Rogers RD, Blackshaw AJ, Middleton HC, Matthews K, Hawtin K, Crowley C, Hopwood A, Wallace C, Deakin JF, Sahakian BJ, Robbins TW (1999a) Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour. Psychopharmacology 146:482–491PubMedGoogle Scholar
  36. Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, Baker NB, Hunter J, Carthy T, Booker E, London M, Deakin JF, Sahakian BJ, Robbins TW (1999b) Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology 20:322–339PubMedGoogle Scholar
  37. Rubinsztein JS, Rogers RD, Riedel WJ, Mehta MA, Robbins TW, Sahakian BJ (2001) Acute dietary tryptophan depletion impairs maintenance of “affective set” and delayed visual recognition in healthy volunteers. Psychopharmacology 154:319–326PubMedGoogle Scholar
  38. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, Robbins TW (1988) A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson’s disease. Brain 111:695–718PubMedGoogle Scholar
  39. Smith TD, Kuczenski R, George-Friedman K, Malley JD, Foote SL (2000) In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administration. Synapse 38:460–470CrossRefPubMedGoogle Scholar
  40. Sparks DL, Markesbery WR (1991) Altered serotonergic and cholinergic synaptic markers in Pick’s disease. Arch Neurol 48:796–799PubMedGoogle Scholar
  41. Swartz JR, Miller BL, Lesser IM, Darby AL (1997) Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 58:212–216PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • J. B. Deakin
    • 1
  • S. Rahman
    • 1
  • P. J. Nestor
    • 2
  • J. R. Hodges
    • 2
  • B. J. Sahakian
    • 1
  1. 1.Department of PsychiatryUniversity of Cambridge, Addenbrooke’s HospitalCambridgeEngland, UK
  2. 2.Department of NeurologyUniversity of Cambridge, Addenbrooke’s HospitalCambridgeEngland, UK

Personalised recommendations